Pds biotechnology reports inducement grants under nasdaq listing rule 5635(c)(4)

Florham park, n.j., april 08, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary versamune® and infectimune™ t-cell activating technologies, today announced that on april 6, 2022 pds biotech granted nonstatutory stock options to (a) robert imani, m.d., phd, pds biotech's vice president medical director to purchase 70,000 shares of pds biotech common stock, and (b) paul ivany, pds biotech's senior director manufacturing operations, to purchase 50,000 shares of pds biotech's common stock, in each case, as a material inducement to their employment with pds biotech and in accordance with nasdaq listing rule 5635(c)(4) and pds biotech's 2019 inducement plan, as amended, which was adopted on june 17, 2019 and provides for the granting of equity awards to new employees of pds biotech.
PDSB Ratings Summary
PDSB Quant Ranking